Series A-2 COMMON STOCK PURCHASE WARRANT ZYVERSA THERAPEUTICS, INC.Security Agreement • November 6th, 2024 • ZyVersa Therapeutics, Inc. • Pharmaceutical preparations
THIS Series A-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time or times on or after the Stockholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the five-year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), up to [•] shares of common stock, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CONFIDENTIAL November 5, 2024Financial Advisory Agreement • November 6th, 2024 • ZyVersa Therapeutics, Inc. • Pharmaceutical preparations • New York
The purpose of this financial advisory agreement (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by ZyVersa Therapeutics, Inc. (the “Company”) to render Financial Services (as defined below) to the Company.
